BEACON_2B | R Documentation |
Kaplan-Meier digitized data from BEACON, figure 2B (PMID 26482278). A reported sample size of 852 for a primary endpoint of OS in breast cancer.
BEACON_2B
A data frame of 852 observations and 3 variables:
time | event time (in months) | |
event | PFS event indicator (0 : no event, 1 : event) |
|
arm | treatment arms (control, etirinotecan_pegol) | |
Perez EA, Awada A, O’Shaughnessy J, et al. Etirinotecan pegol (NKTR-102) versus treatment of physician’s choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2015; 16: 1556–68.
summary(BEACON_2B)
kmplot(BEACON_2B)
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.